Outcomes of Ultrafiltration in community-based hospitals

We sought to examine outcomes of ultrafiltration in real world community-based hospital settings. Ultrafiltration (UF) is an accepted therapeutic option for advanced decompensated heart failure (ADHF). the feasibility of UF in a community hospital setting, by general cardiologists in a start-up prog...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current problems in cardiology 2024-10, Vol.49 (10), p.102716, Article 102716
Hauptverfasser: Chinta, Viswanath R., Theella, Neelima P., Raja, Joel M., Rawal, Aranyank, Bath, Anandbir, Jones, David, Ibrahim, Atif, Asbeutah, Abdul Aziz A., Adeboye, Adedayo A., Akbilgic, Oguz, Khouzam, Rami N., Stamper, James J., Jefferies, John L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We sought to examine outcomes of ultrafiltration in real world community-based hospital settings. Ultrafiltration (UF) is an accepted therapeutic option for advanced decompensated heart failure (ADHF). the feasibility of UF in a community hospital setting, by general cardiologists in a start-up program had not been objectively evaluated. We retrospectively analyzed the first-year cohort of ADHF patients treated with UF from 10/1/2019 to 10/1/2020, which totaled 30 patients, utilizing the CHF Solutions Aquadex FlexFlow™ System with active UF rate titration. Baseline patient characteristics were similar to RCTs: mean age 63, 73 % male; 27 % female; 53 % Caucasian; 47 % African American; 77 % had LVEF ≤ 40. The baseline mean serum creatinine (Cr) was 1.84 ±0.62 mg/dL, mean GFR of 36.95 ±9.60 ml/min. HF re-admission rates were not significantly different than prior studies (17.2 % at 30 d, 23.3 % at 60 d, but in our cohort, per patient HF re-admission rates were reduced significantly by 60 d (0.30 p = 0.017). Our analysis showed success with UF in mainstream setting with reproducible results of significant volume loss without adverse renal effect, mitigation of recurrent Hdmissions, and remarkable subjective clinical benefit.
ISSN:0146-2806
1535-6280
1535-6280
DOI:10.1016/j.cpcardiol.2024.102716